Puma Biotechnology
PBYI
157 hedge funds and large institutions have $242M invested in Puma Biotechnology in 2026 Q1 according to their latest regulatory filings, with 29 funds opening new positions, 61 increasing their positions, 38 reducing their positions, and 18 closing their positions.
77,400% more call options, than puts
Call options by funds: $775K | Put options by funds: $1K
61% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 18
61% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 38
15% more capital invested
Capital invested by funds: $210M → $242M (+$31.6M)
4.28% more ownership
Funds ownership: 70.14% → 74.42% (+4.3%)
4% more funds holding
Funds holding: 151 → 157 (+6)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$9.42M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
+$5.02M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$2.62M |
| 4 |
American Century Companies
Kansas City,
Missouri
|
+$1.72M |
| 5 |
State Board of Administration of Florida Retirement System
Tallahassee,
Florida
|
+$1.58M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$1.17M |
| 2 |
Mackenzie Financial
Toronto Ontario,
Ontario, Canada
|
-$966K |
| 3 |
Two Sigma Investments
New York
|
-$963K |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$856K |
| 5 |
Los Angeles Capital Management
Los Angeles,
California
|
-$809K |
PBYI Hedge Fund Activity: Q1 2026 in Review
157 of the 8,191 institutional investors tracked by Wall St. Rank reported a position in Puma Biotechnology (PBYI) for Q1 2026, worth a combined $242M — up 15% from $210M a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new PBYI positions and 18 closed out — a net gain of 11 holders — while 61 added to existing stakes and 38 trimmed.
The largest buyer was Millennium Management, adding an estimated $9.42M. The largest seller was Renaissance Technologies, cutting an estimated $1.17M.
- 157 institutional investors held Puma Biotechnology (PBYI) as of Q1 2026, up from 151 in Q4 2025.
- Funds reported $242M of Puma Biotechnology stock for Q1 2026, up 15% quarter-over-quarter.
- 29 funds opened new Puma Biotechnology positions in Q1 2026 and 18 closed out, a net change of +11 holders.
- The largest Puma Biotechnology buyer in Q1 2026 was Millennium Management, an estimated $9.42M added.
- The largest Puma Biotechnology seller in Q1 2026 was Renaissance Technologies, an estimated $1.17M sold.
Based on aggregated 13F filings for Q1 2026.